| Milestones |
 |
Mechanism of contrast induced nephrotoxicity elucidated by Dr. Richard Katholi – 1992 |
|
Over 200 major clinical trials successfully completed |
|
Over 225 major research grants awarded |
|
Three US patents awarded to PERC investigators |
|
Over 50,000 patients entered into clinical databases (Lipid database, PTCA and stent database, peripheral international database) |
|
Over 100 manuscripts, review articles, books and abstracts published by PERC investigators |
|
First cardiology center in the world to infuse vascular endothalial growth factor (VEGF) into human coronary arteries – 1996 |
|
PERC expand services from local to national clinical trial management. |
|
Multi-center management of one of the fastest enrolling SFA clinical trials. – 2003 |
|
Acquisition of first multi-million dollar national clinical trial project. - 2006 |
|
PERC facility expansion from 5,000 sq. ft. to 12,500. - 2008 |
|
Introduction of SynvaCor a Angiographic Core Lab and Wound Core Lab dedicated to the periphery. – 2008 |
